Literature DB >> 10404543

Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall.

M Abou-Karam1, W T Shier.   

Abstract

Inhibitors of oncogene product enzyme activity were sought as a prescreen for potential cancer chemopreventive agents. Purpurogallin, a polyphenol from Quercus sp. nutgall, was found to inhibit the tyrosine-specific protein kinase of the human erb-b oncogene product (epidermal growth factor receptor) for both autophosphorylation (IC50 = 27.5 microM) and phosphorylation of an exogenous substrate (IC50 = 45.3 microM). An examination of enzyme kinetics indicated that purpurogallin is a competitive inhibitor of both ATP (Ki = 54.9 microM for autophosphorylation, Ki = 33.9 microM for phosphorylation of exogenous substrate) and the tyrosine-containing acceptor substrate poly(glutamate, alanine, tyrosine) 6:3:1 (Ki = 83.7 microM).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404543     DOI: 10.1002/(SICI)1099-1573(199906)13:4<337::AID-PTR451>3.0.CO;2-J

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  7 in total

Review 1.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

2.  Synthesis of Naturally Occurring Tropones and Tropolones.

Authors:  Na Liu; Wangze Song; Casi M Schienebeck; Min Zhang; Weiping Tang
Journal:  Tetrahedron       Date:  2014-12-09       Impact factor: 2.457

3.  Conversion of lignin-derived 3-methoxycatechol to the natural product purpurogallin using bacterial P450 GcoAB and laccase CueO.

Authors:  Shun Zhang; Xiaofeng Wu; Yi Xiao
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-31       Impact factor: 4.813

Review 4.  Selected approaches for rational drug design and high throughput screening to identify anti-cancer molecules.

Authors:  Michael Hedvat; Luni Emdad; Swadesh K Das; Keetae Kim; Santanu Dasgupta; Shibu Thomas; Bin Hu; Shan Zhu; Rupesh Dash; Bridget A Quinn; Regina A Oyesanya; Timothy P Kegelman; Upneet K Sokhi; Siddik Sarkar; Eda Erdogan; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Martin G Pomper; Jun Wei; Bainan Wu; John L Stebbins; Paul W Diaz; John C Reed; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Anticancer Agents Med Chem       Date:  2012-11       Impact factor: 2.505

Review 5.  Gallnuts: A Potential Treasure in Anticancer Drug Discovery.

Authors:  Jiayu Gao; Xiao Yang; Weiping Yin; Ming Li
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-29       Impact factor: 2.629

6.  Inhibitory Effect of Purpurogallin on Osteoclast Differentiation in Vitro through the Downregulation of c-Fos and NFATc1.

Authors:  Kiryeong Kim; Tae Hoon Kim; Hye Jung Ihn; Jung Eun Kim; Je-Yong Choi; Hong-In Shin; Eui Kyun Park
Journal:  Int J Mol Sci       Date:  2018-02-17       Impact factor: 5.923

7.  Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo.

Authors:  Sae-Kwang Ku; Jong-Sup Bae
Journal:  BMB Rep       Date:  2014-07       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.